Document Detail

Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases.
MedLine Citation:
PMID:  9758439     Owner:  NLM     Status:  MEDLINE    
Stimulatory therapy with either GnRH or gonadotropins is an effective treatment to induce spermatogenesis and achieve paternity in men with secondary hypogonadism. However, there is still uncertainty about the optimal treatment modality and schedule, the duration of treatment necessary and the influence of interfering factors such as maldescended testes. We have extended our previous series of men treated for secondary hypogonadism and now present our therapeutic experience with 42 cases. Twenty-one patients with hypothalamic disorders (11 with idiopathic hypogonadotropic hypogonadism (IHH) and 10 with Kallmann syndrome (KalS)) were treated with GnRH (group Ia) or human chorionic gonadotropin (hCG)/human menopausal gonadotropin (hMG) (group Ib), and 21 patients with hypopituitarism (group II) were treated with hCG/hMG. A total of 5 7 treatment courses were initiated for induction of spermatogenesis, 36 of these for the purpose of induction of pregnancy in the female partner. Bilateral testicular volumes doubled within 5-12 months of therapy. Spermatogenesis as evidenced by the appearance of sperm in the ejaculate was induced in 54/57 courses. Pregnancies occurred in 26/36 courses. Unilaterally maldescended testes did not preclude patients with IHH or KalS from gaining fertility under therapy and spermatogenesis could be successfully initiated even in some individuals with bilateral maldescended testes. In general there was a tendency for a longer duration of therapy until induction of spermatogenesis in patients with a history of bilateral cryptorchidism. However, this did not reach statistical significance. In patients with IHH or KalS treated with either hCG/hMG or GnRH there were no statistically significant differences in terms of duration to appearance of sperm or pregnancy rates. Even in KalS patients as old as 43 years spermatogenesis could be induced. In repeatedly treated patients stimulation of spermatogenesis tended to be faster while time until induction of pregnancy was significantly shorter in the second treatment course. In conclusion, GnRH or hCG/hMG are effective therapeutic modalities for patients with IHH or KalS. It remains to be determined whether highly purified urinary gonadotropin preparations or recombinant LH and FSH will provide therapeutic advantages.
D Büchter; H M Behre; S Kliesch; E Nieschlag
Related Documents :
10740329 - Length of use and symptoms associated with premature removal of the levonorgestrel intr...
19665279 - Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized...
9693399 - Diagnostic and therapeutic decision-making with transvaginal sonography for first trime...
19249029 - Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilizatio...
6588959 - Dysfunctional uterine bleeding in women over 40 years of age.
9782139 - Ultrasonographic prediction of the efficacy of gnrh agonist therapy before laparoscopic...
3669269 - Intravenous isosorbide dinitrate infusion in the management of unstable angina pectoris...
23942989 - Lateral ankle instability in high-demand athletes: reconstruction with fibular perioste...
3045069 - Topically applied vidarabine sodium phosphate in genital herpes infection.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  139     ISSN:  0804-4643     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-10-09     Completed Date:  1998-10-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  298-303     Citation Subset:  IM    
Institute of Reproductive Medicine of the University, Münster, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chorionic Gonadotropin / administration & dosage,  therapeutic use*
Fertility / drug effects,  physiology
Gonadotropin-Releasing Hormone / administration & dosage,  therapeutic use*
Hypogonadism / drug therapy*,  pathology
Menotropins / administration & dosage,  therapeutic use*
Retrospective Studies
Spermatogenesis / drug effects,  physiology
Testis / pathology
Time Factors
Reg. No./Substance:
0/Chorionic Gonadotropin; 33515-09-2/Gonadotropin-Releasing Hormone; 61489-71-2/Menotropins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iodide induces thyroid autoimmunity in patients with endemic goitre: a randomised, double-blind, pla...
Next Document:  High serum luteinizing hormone levels induce ovarian delta4 cytochrome P450c17alpha down-regulation ...